GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cuorips Inc (TSE:4894) » Definitions » Return-on-Tangible-Equity

Cuorips (TSE:4894) Return-on-Tangible-Equity : 0.00% (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cuorips Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cuorips's annualized net income for the quarter that ended in Sep. 2024 was 円0.00 Mil. Cuorips's average shareholder tangible equity for the quarter that ended in Sep. 2024 was 円5,764.69 Mil. Therefore, Cuorips's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Cuorips's Return-on-Tangible-Equity or its related term are showing as below:

TSE:4894' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -13.43   Med: -10.78   Max: -7.29
Current: -10.65

During the past 4 years, Cuorips's highest Return-on-Tangible-Equity was -7.29%. The lowest was -13.43%. And the median was -10.78%.

TSE:4894's Return-on-Tangible-Equity is ranked better than
69.94% of 1261 companies
in the Biotechnology industry
Industry Median: -43.85 vs TSE:4894: -10.65

Cuorips Return-on-Tangible-Equity Historical Data

The historical data trend for Cuorips's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cuorips Return-on-Tangible-Equity Chart

Cuorips Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Return-on-Tangible-Equity
-7.29 -9.25 -12.31 -13.43

Cuorips Quarterly Data
Mar21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only -14.26 -10.62 -11.55 -8.55 -

Competitive Comparison of Cuorips's Return-on-Tangible-Equity

For the Biotechnology subindustry, Cuorips's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cuorips's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cuorips's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Cuorips's Return-on-Tangible-Equity falls into.


;
;

Cuorips Return-on-Tangible-Equity Calculation

Cuorips's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2024 )  (A: Mar. 2023 )(A: Mar. 2024 )
=-632.183/( (3448.122+5965.198 )/ 2 )
=-632.183/4706.66
=-13.43 %

Cuorips's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2024 )  (Q: Mar. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Mar. 2024 )(Q: Sep. 2024 )
=0/( (5965.198+5564.184)/ 2 )
=0/5764.691
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Cuorips  (TSE:4894) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Cuorips Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Cuorips's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Cuorips Business Description

Industry
Traded in Other Exchanges
N/A
Address
3-11-5 Nihonbashi-Honcho, 507, Nihonbashi Life Science Building 2, Chuo-ku, Tokyo, JPN, 103-0023
Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.

Cuorips Headlines

No Headlines